BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Black Diamond Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.81+0.09 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $103.83M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.0%
35M of 57M shares
Institutional holders
96
25 new, 32 sold out
Net institutional buying
-3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BB Biotech AG | 8,517,839 | 15.10% | 13G (passive) amendment | Dec 31, 2024 |
| Ali Behbahani | 4,546,947 | 8.10% | 13D (active) amendment | May 9, 2024 |
| Versant Ventures VI GP-GP, LLC | 4,328,883 | 7.70% | 13D (active) amendment | Aug 6, 2024 |
| T. Rowe Price Investment Management, Inc. | 4,028,202 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,838,590 | 6.70% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BDTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 4,448,757 | 7.74% | $8.23M | – | 0.52% |
| T. Rowe Price Investment Management, Inc. | 4,028,202 | 7.01% | $7.45K | −6,534,901 | 0.00% |
| BlackRock, Inc. | 3,917,088 | 6.82% | $7.25M | +2,810,248 | 0.00% |
| Acadian Asset Management LLC | 2,348,651 | 4.09% | $4.34K | – | 0.01% |
| Vanguard Capital Management LLC | 2,125,270 | 3.70% | $3.93M | +274,802 | 0.00% |
| Renaissance Technologies LLC | 1,962,394 | 3.42% | $3.63M | +318,647 | 0.00% |
| Defilade Capital Management, L.P. | 1,674,999 | 2.92% | $3.10M | New | 0.41% |
| Dimensional Fund Advisors LP | 1,365,384 | 2.38% | $2.53M | +63,720 | 0.00% |
| Geode Capital Management, LLC | 1,218,171 | 2.12% | $2.25M | +681,596 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 1,092,885 | 1.90% | $2.02M | +34,488 | 0.00% |
| AWM Investment Company, Inc. | 1,000,000 | 1.74% | $1.85M | +475,000 | 0.16% |
| Marshall Wace, Llp | 896,602 | 1.56% | $1.66M | +60,336 | 0.00% |
| Bridgeway Capital Management, LLC | 791,434 | 1.38% | $1.46M | +67,957 | 0.03% |
| FMR LLC | 643,668 | 1.12% | $1.19M | +19,841 | 0.00% |
| Balyasny Asset Management L.P. | 542,172 | 0.94% | $1.00M | +31,361 | 0.00% |
| State Street Corp | 525,013 | 0.91% | $971.27K | +311,500 | 0.00% |
| Bank Of America Corp /De/ | 413,516 | 0.72% | $765.00K | +299,373 | 0.00% |
| Vanguard Portfolio Management LLC | 407,074 | 0.71% | $753.09K | +313,894 | 0.00% |
| Northern Trust Corp | 365,394 | 0.64% | $675.98K | −99,314 | 0.00% |
| Bank of New York Mellon Corp | 318,763 | 0.55% | $589.71K | +129,615 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 35M | 61.0% | 25 / 35 | 24 / 32 | 9M | 13M |
| Q1 2026 | 104 | 39M | 67.0% | 23 / 30 | 35 / 21 | 9M | 8M |
| Q4 2025 | 104 | 40M | 70.0% | 27 / 38 | 24 / 12 | 10M | 9M |
| Q3 2025 | 91 | 39M | 67.5% | 21 / 28 | 23 / 24 | 5M | 5M |
| Q2 2025 | 94 | 39M | 67.4% | 37 / 27 | 16 / 27 | 4M | 6M |
| Q1 2025 | 84 | 41M | 70.9% | 14 / 19 | 28 / 16 | 2M | 9M |
| Q4 2024 | 87 | 48M | 83.4% | 20 / 34 | 17 / 28 | 5M | 6M |
| Q3 2024 | 96 | 49M | 84.8% | 23 / 37 | 21 / 16 | 12M | 7M |
| Q2 2024 | 90 | 47M | 81.4% | 31 / 25 | 19 / 27 | 15M | 8M |
| Q1 2024 | 88 | 40M | 68.9% | 26 / 24 | 22 / 14 | 7M | 7M |
| Q4 2023 | 76 | 39M | 67.8% | 18 / 24 | 17 / 13 | 7M | 4M |
| Q3 2023 | 73 | 37M | 64.7% | 17 / 23 | 15 / 17 | 5M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BDTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. | 2,119,709 | 3.69% | $3.92M | 0.04% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,556,251 | 2.71% | $2.88M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,209,182 | 2.10% | $2.24M | 0.00% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 521,043 | 0.91% | $963.93K | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 513,120 | 0.89% | $867.17K | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 511,250 | 0.89% | $945.81K | 0.00% | Jun 30, 2026 |
| iShares U.S. Small-Cap Equity Factor ETF | 469,215 | 0.82% | $792.97K | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 465,655 | 0.81% | $861.46K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Fund | 375,000 | 0.65% | $693.75K | 0.70% | Jun 30, 2026 |
| iShares Biotechnology ETF | 347,116 | 0.60% | $642.16K | 0.01% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 341,219 | 0.59% | $576.66K | 0.00% | Jul 31, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 248,134 | 0.43% | $459.05K | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 240,495 | 0.42% | $533.90K | 0.00% | May 31, 2026 |
| Dimensional US Small Cap Value ETF | 210,208 | 0.37% | $355.25K | 0.00% | Jul 31, 2026 |
| Small Cap Value Portfolio | 182,571 | 0.32% | $337.76K | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark A. Velleca | PRESIDENT & CEO, Director | 121,522 | 0.21% | Jan 23, 2026 |
| Brent Hatzis-Schoch | SEE REMARKS | 83,400 | 0.15% | Jan 23, 2026 |
| Sergey Yurasov | CHIEF MEDICAL OFFICER | 75,000 | 0.13% | Jan 23, 2026 |
| Erika Jones | SEE REMARKS | 85,150 | 0.15% | Jan 23, 2026 |
| Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | 170,192 | 0.30% | Jan 23, 2026 |
| Ali Behbahani | Director | 4,558,993 | 7.94% | Sep 21, 2026 |
| Prakash Raman | Director | 51,840 | 0.09% | Sep 21, 2026 |
| Kapil Dhingra | Director | 10,000 | 0.02% | Jun 29, 2026 |
| Samarth Kulkarni | Director | – | – | Jun 29, 2026 |
| Garry E. Menzel | Director | 76,644 | 0.13% | Jun 29, 2026 |
| Shannon Campbell | Director | 8,865 | 0.02% | Jun 29, 2026 |
| Biotech Ag Bb | 10% owner | 8,117,839 | 14.13% | Mar 20, 2025 |
| Growth N. V. Biotech | 10% owner | 3,233,547 | 5.63% | Mar 20, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ali Behbahani Director | Sep 18, 2026 | Award | +7,707 | $1.93 | $14.87K | 110,236 |
| Prakash Raman Director | Sep 18, 2026 | Award | +6,801 | $1.93 | $13.13K | 51,840 |
| Prakash Raman Director | Jun 19, 2026 | Award | +7,907 | $1.66 | $13.13K | 45,039 |
| Ali Behbahani Director | Jun 19, 2026 | Award | +8,961 | $1.66 | $14.88K | 102,529 |
| Prakash Raman Director | Mar 20, 2026 | Award | +6,105 | $2.15 | $13.13K | 37,132 |
| Ali Behbahani Director | Mar 20, 2026 | Award | +6,919 | $2.15 | $14.88K | 93,568 |
| Prakash Raman Director | Dec 12, 2025 | Award | +4,665 | $2.76 | $12.88K | 31,027 |
| Ali Behbahani Director | Dec 12, 2025 | Award | +5,208 | $2.76 | $14.37K | 86,649 |
| Prakash Raman Director | Sep 19, 2025 | Award | +3,843 | $3.35 | $12.87K | 26,362 |
| Ali Behbahani Director | Sep 19, 2025 | Award | +4,291 | $3.35 | $14.37K | 81,441 |
| Prakash Raman Director | Jun 20, 2025 | Award | +5,526 | $2.33 | $12.88K | 22,519 |
| Ali Behbahani Director | Jun 20, 2025 | Award | +6,170 | $2.33 | $14.38K | 77,150 |
| Prakash Raman Director | Mar 21, 2025 | Award | +6,848 | $1.88 | $12.87K | 16,993 |
| Ali Behbahani Director | Mar 21, 2025 | Award | +7,646 | $1.88 | $14.37K | 70,980 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −584,292 | $1.95 | $1.14M | 3,233,547 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −300,000 | $1.94 | $582.00K | 7,217,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −1,000,000 | $2.31 | $2.31M | 6,217,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −2,000,000 | $2.00 | $4.00M | 4,217,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −1,000,000 | $2.07 | $2.07M | 7,517,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −500,000 | $2.12 | $1.06M | 2,733,547 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −400,000 | $2.09 | $836.00K | 3,817,839 |
| Erika Jones SEE REMARKS | Jan 30, 2025 | Award | +75,000 | – | – | 85,150 |
| Brent Hatzis-Schoch SEE REMARKS | Jan 30, 2025 | Award | +75,000 | – | – | 83,400 |
| Mark A. Velleca PRESIDENT & CEO, Director | Jan 30, 2025 | Award | +75,000 | – | – | 121,522 |
| Sergey Yurasov CHIEF MEDICAL OFFICER | Jan 30, 2025 | Award | +75,000 | – | – | 75,000 |
| Elizabeth Buck CHIEF SCIENTIFIC OFFICER | Jan 30, 2025 | Award | +75,000 | – | – | 170,192 |
| Shannon Campbell Director | Dec 13, 2024 | Award | +4,500 | $2.50 | $11.25K | 8,865 |
| Prakash Raman Director | Dec 13, 2024 | Award | +5,150 | $2.50 | $12.88K | 10,145 |
| Ali Behbahani Director | Dec 13, 2024 | Award | +5,750 | $2.50 | $14.38K | 63,334 |
| Shannon Campbell Director | Sep 20, 2024 | Award | +2,354 | $4.78 | $11.25K | 4,365 |
| Prakash Raman Director | Sep 20, 2024 | Award | +2,694 | $4.78 | $12.88K | 4,995 |
| Ali Behbahani Director | Sep 20, 2024 | Award | +3,007 | $4.78 | $14.37K | 57,584 |
| Versant Voyageurs I Parallel, L.P. 10% owner | Aug 28, 2024 | Sale | −221,600 | $6.32 | $1.40M | 3,726,341 |
| Ali Behbahani Director | Jun 21, 2024 | Award | +2,887 | $4.98 | $14.38K | 54,577 |
| Shannon Campbell Director | Jun 21, 2024 | Award | +2,011 | $4.98 | $10.01K | 2,011 |
| Prakash Raman Director | Jun 21, 2024 | Award | +2,301 | $4.98 | $11.46K | 2,301 |
| Ali Behbahani Director | Mar 15, 2024 | Award | +3,166 | $4.54 | $14.37K | 51,690 |
| Wendy L. Dixon Director | Mar 15, 2024 | Award | +3,253 | $4.54 | $14.77K | 38,054 |
| Wendy L. Dixon Director | Dec 15, 2023 | Award | +4,043 | $2.73 | $11.04K | 34,801 |
| Ali Behbahani Director | Dec 15, 2023 | Award | +4,455 | $2.73 | $12.16K | 48,524 |
| Growth N. V. Biotech 10% owner | Oct 17, 2023 | Buy | +400,000 | $2.34 | $936.00K | 8,517,839 |
| Wendy L. Dixon Director | Sep 15, 2023 | Award | +2,986 | $3.60 | $10.75K | 30,758 |
| Ali Behbahani Director | Sep 15, 2023 | Award | +3,299 | $3.60 | $11.88K | 44,069 |
| Mark A. Velleca PRESIDENT & CEO, Director | Sep 15, 2023 | Award | +5,208 | $3.60 | $18.75K | 46,522 |
| Ra Capital Management, L.P. Director | Jul 5, 2023 | Buy | +935,850 | $5.00 | $4.68M | 3,213,828 |
| Ali Behbahani Director | Jul 5, 2023 | Buy | +1,000,000 | $5.00 | $5.00M | 4,448,757 |
| Biotech Ag Bb 10% owner | Jun 30, 2023 | Buy | +1,000,000 | $5.00 | $5.00M | 8,117,839 |
| Growth N. V. Biotech 10% owner | Jun 27, 2023 | Buy | +1,740,000 | $5.49 | $9.55M | 7,117,839 |
| David M. Epstein SEE REMARKS, Director | Jun 27, 2023 | Sale(10b5-1 plan) | −25,000 | $6.70 | $167.50K | 671,423 |
| Mark A. Velleca Director | Jun 16, 2023 | Award | +8,929 | $2.10 | $18.75K | 41,314 |
| Ali Behbahani Director | Jun 16, 2023 | Award | +5,655 | $2.10 | $11.88K | 40,770 |
| Wendy L. Dixon Director | Jun 16, 2023 | Award | +5,119 | $2.10 | $10.75K | 27,772 |
| Mark A. Velleca Director | Mar 16, 2023 | Award | +11,228 | $1.67 | $18.75K | 32,385 |
| Wendy L. Dixon Director | Mar 16, 2023 | Award | +6,437 | $1.67 | $10.75K | 22,653 |
| Ali Behbahani Director | Mar 16, 2023 | Award | +7,111 | $1.67 | $11.88K | 35,115 |
| Erika Jones SEE REMARKS | Feb 13, 2023 | Award | +5,075 | – | – | 10,150 |
| Fang Ni SEE REMARKS | Dec 22, 2022 | Buy | +36,363 | $1.28 | $46.54K | 125,389 |
| Fang Ni SEE REMARKS | Dec 21, 2022 | Buy | +20,000 | $1.29 | $25.80K | 89,026 |
| Wendy L. Dixon Director | Dec 16, 2022 | Award | +7,167 | $1.50 | $10.75K | 16,216 |
| Ali Behbahani Director | Dec 16, 2022 | Award | +7,917 | $1.50 | $11.88K | 28,004 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Epstein David Former Employer | Jul 31, 2024 | 50,000 | $310.00K | Jul 31, 2024 | Founder Shares |
| Epstein David Former Employee | Jul 26, 2024 | 50,000 | $310.00K | Jul 26, 2024 | Founder Shares |
| Epstein David Former Employer | Jul 16, 2024 | 50,000 | $312.50K | Jul 16, 2024 | Founder Shares |
| Epstein David Former Employer | Jul 11, 2024 | 69,024 | $345.12K | Jul 11, 2024 | Founder Shares |
| Esptein David Former Employee | Jul 9, 2024 | 75,000 | $360.00K | Jul 9, 2024 | Founder Shares |
| Epstein David Former Employer | Jun 28, 2024 | 50,000 | $250.00K | Jun 28, 2024 | Founder Shares |
| Epstein David Former Board Member | Jun 27, 2024 | 40,353 | $189.66K | Jun 27, 2024 | Founder Shares |
| Epstein David Former Board Member | Jun 26, 2024 | 9,647 | $45.34K | Jun 26, 2024 | Founders Shares |
| Epstein David Former Board Member | Jun 24, 2024 | 6,011 | $30.18K | Jun 24, 2024 | Founders Shares |
| Epstein David Former Board Member | Jun 21, 2024 | 743 | $3.72K | Jun 21, 2024 | Founders Shares |
| Epstein David Former board member | Jun 20, 2024 | 20,143 | $101.12K | Jun 20, 2024 | Founder Shares |
| Wu Leah Spouse of former board member | Jun 20, 2024 | 20,268 | $101.75K | Jun 20, 2024 | Founders Shares |
| Epstein David Former Board Member | Jun 18, 2024 | 2,951 | $16.08K | Jun 18, 2024 | Founders Shares |
| Epstein David Former Board Member | Jun 14, 2024 | 24,621 | $148.46K | Jun 14, 2024 | Founders Shares |
| Epstein David Former Board Member | Jun 13, 2024 | 70,853 | $435.75K | Jun 13, 2024 | Founders Shares |